601607 上海医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入222,963,9803.67%283,579,601275,250,935260,295,089231,981,300
减:营业总成本216,372,9783.33%276,283,477267,676,307253,008,864224,907,251
    其中:营业成本199,499,4133.55%253,163,121244,619,261228,966,947201,494,923
               财务费用1,014,288-9.02%1,407,2241,480,9121,485,7581,313,192
               资产减值损失(47,896)-93.93%(1,018,556)(614,374)(561,277)(331,471)
公允价值变动收益66,111-41.57%332,121203,854404,731218,738
投资收益1,007,865-70.09%3,170,144380,427(68,123)533,117
    其中:对联营企业和合营企业的投资收益101,343-78.87%284,473521,909129,329526,743
营业利润7,572,312-9.17%9,942,0868,140,7137,667,2359,014,650
利润总额7,556,124-8.94%9,819,8058,020,0077,054,2978,808,353
减:所得税费用1,789,792-22.59%2,846,0872,149,9951,887,7261,816,339
净利润5,766,332-3.67%6,973,7185,870,0115,166,5706,992,015
减:非控股权益1,180,36840.67%1,249,1601,317,4831,398,5711,374,863
股东净利润4,585,964-10.90%5,724,5584,552,5283,768,0005,617,152

市场价值指针
每股收益 (元) *1.240-10.79%1.5401.2301.0201.610
每股派息 (元) *0.100-16.67%0.4700.3700.4100.610
每股净资产 (元) *21.3964.70%20.46519.33018.50018.137
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容